Gusacitinib (ASN002), a dual JAK-SYK inhibitor (Figure 3b), exhibited a broadened spectrum of targeted cytokines (Th2, Th17/Th22, and Th1 pathways) in AD [197]. This evidence concerns the gene SYK and Alzheimer disease.